Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 23 | -0.72 Increased by +17.24% | -0.39 Decreased by -216.96% |
| Feb 8, 23 | -0.72 Increased by +25.00% | -0.51 Decreased by -80.74% |
| Nov 8, 22 | -0.82 Increased by +8.89% | -0.78 Decreased by -6.57% |
| Aug 8, 22 | -0.31 Increased by +65.93% | -0.93 Increased by +71.68% |
| May 5, 22 | -0.87 Decreased by -1.16% | -0.98 Increased by +11.45% |
| Feb 28, 22 | -0.96 Decreased by -1.05% | -0.69 Decreased by -56.71% |
| Nov 4, 21 | -0.90 Increased by +2.17% | -0.94 Increased by +4.53% |
| Aug 9, 21 | -0.91 Increased by +20.18% | -0.89 Decreased by -2.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 1.23 M Decreased by -83.24% | -74.77 M Increased by +15.02% | Decreased by -6.10 K% Decreased by -406.95% |
| Dec 31, 22 | 221.00 K Decreased by -97.07% | -74.57 M Increased by +20.11% | Decreased by -33.74 K% Decreased by -2.63 K% |
| Sep 30, 22 | 4.46 M Decreased by -16.96% | -84.09 M Increased by +0.68% | Decreased by -1.89 K% Decreased by -19.62% |
| Jun 30, 22 | 51.58 M Increased by +1.23 K% | 18.47 M Increased by +122.04% | Increased by +35.80% Increased by +101.65% |
| Mar 31, 22 | 7.31 M Increased by +105.91% | -87.99 M Decreased by -12.33% | Decreased by -1.20 K% Increased by +45.45% |
| Dec 31, 21 | 7.55 M Increased by +N/A% | -93.35 M Decreased by -14.81% | Decreased by -1.24 K% Decreased by N/A% |
| Sep 30, 21 | 5.37 M Increased by +N/A% | -84.66 M Decreased by -13.88% | Decreased by -1.58 K% Decreased by N/A% |
| Jun 30, 21 | 3.87 M Increased by +N/A% | -83.79 M Decreased by -8.18% | Decreased by -2.17 K% Decreased by N/A% |
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.